Seoul Economic Daily EnglishCodex · 实盘可交易 · 做多市场:韩股▼ 亏 -4.70% · 已结算把握 5/10
北京时间·🕒 发布 15:26:07(首尔 16:26)·⟳ 抓取 15:40:24 +14m17s·⚡ 决策 08-24 15:45:52 +5m28s·64.2 天前
韩美药品将肥胖代谢候选药HM17321授权给Genentech，最高交易额约23亿美元
事件对韩美药品为明确一阶利好，但事件日已经触及韩国30%涨停，执行上只适合次日限价小仓，不追高。
📄 原文Seoul Economic Daily English↗ 原文
Hanmi Lands $2.3 Billion Obesity Drug Deal, Its Biggest Ever
Hanmi Pharmaceutical has secured the largest drug licensing deal in its history since the death of founder Lim Sung-ki,…
▼ 亏 -4.70%入场 08-25 开盘 @550,000 → 离场 08-26 开盘 @527,000
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑大额授权确认，只在涨停后不追高低吸
怎么买 限价买入 不高于 540000、2 个交易日内有效
怎么卖 止盈 +6%(半仓)/+12%(清仓) · 止损 -7% · 时间止损 3日
不做 Roche Holding（RHHBY.US）
Roche是买方且体量巨大，早期管线引入对短线财务和估值增量不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 128940.KS 韩美药品
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 128940.KS 韩美药品
| 收益状态 | -4.70% 已平仓 |
|---|---|
| 进场成交 | 2026-08-25 · 开盘 · @550000 |
| 离场成交 | 2026-08-26 · 开盘 · @527000 |
| 毛收益 | -4.18% |
| 成本 | +0.52% |
| 净收益 | -4.70% |
| 计入收益 | -4.70% |
| 建仓日 | 2026-08-25 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 19:39
研究档案
结论摘要
韩美药品把一期阶段的HM17321授权给Genentech，首付款1.9亿美元约占事件前市值5.27万亿韩元的约5%，最高交易额约占约61%，且保留韩国权益和上市后分成，基本面验证强；但公司股价在8月24日已涨29.96%至54万韩元，价格已完成第一轮重定价，因此只给次日不追高的条件单。
消息传播链
- 公司通稿披露与Genentech签署HM17321独家授权，最高23亿美元、含1.9亿美元首付款。
- 韩国财经媒体午前已报道韩美药品向Genentech技术输出。
- Yonhap韩文稿确认金额、首付款、韩国以外权益和二期后由Genentech负责。
- 128940.KS报价54万韩元，较前收涨29.96%，已接近或达到韩国个股涨停。市场反应:韩美药品（128940.KS）涨29.96%，成交额约5944亿韩元。
关键理由
- 首付款约1.9亿美元约合2629亿至2850亿韩元，相当于韩美药品事件前市值约5.27万亿韩元的约5%，现金增量不只是远期叙事。
- HM17321仍处一期，但Genentech接手二期后全球开发，提升了肥胖代谢管线外部验证与后续里程碑概率。
- 事件当日已涨停，交易边际从追利好转为只在次日未继续大幅溢价时参与。
主要风险
- HM17321仍为早期临床资产，23.05亿美元大部分是远期里程碑，不应按全额一次性资本化。
- 128940.KS已在事件日上涨29.96%至涨停，次日若继续高开或封板，短线性价比迅速恶化。
反向证据
- 做多前查反向 · 来源 web · 日期 2019-07-04 · 影响 weakens
同公司历史上Janssen退回肥胖药权利导致股价大跌，提示早期授权资产远期兑现风险高。
检索:Hanmi HM17321 Genentech license phase 1 risk rights returned obesity drug 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-24 · 影响 weakens
事件当日韩美药品已涨29.96%至54万韩元，第一轮利好已被价格充分反映。
检索:Hanmi Pharm HM17321 Genentech stock upper limit August 24 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例支持方向为多，但因当前已经首日涨停，将订单从追高改为次日限价小仓。
方向:同主体历史license-out先例方向明显偏正，尤其大额首付款和跨国药企背书会触发韩股快速重估。
涨幅量级:高相似样本显示首日可达韩国涨停级别，但当前事件首日已经完成29.96%反应，不能再用先例涨幅支持追高。
形态:2019年权利退回显示早期管线授权的远期里程碑存在较大回撤风险，适合压仓位和收紧买点。
历史先例(按相似度)
- 相似度 8/10 128940 2015-11-06 韩美药品与Sanofi签署糖尿病治疗组合授权，最高约39亿欧元，次日股价涨30%。 原文 ↗
测韩美药品（128940.KS）公告后首个交易日反应。
⚠来源层级不符(声明wire/实为media) — 该行涨幅别用来定止盈止损
相似度依据:同为韩美药品向大型跨国药企授权代谢疾病资产，且首付款和最高交易额均对市值有显著影响。
经验:大额且一手确认的韩系药企license-out可触发首日涨停，但后续追高需看已反应幅度。 - 相似度 7/10 128940 2015-11-09 韩美药品与Janssen签署约9.15亿美元HM12525A糖尿病/肥胖资产授权，股价再涨逾15%。 原文 ↗
事件后 +1日 +15.9% · +2日 +10.3% · +3日 +15.1% · +4日 +11.0% · +5日 +7.6%
⚠锚前1-2日已异动30.0%>锚定日15.9%·盘中首发但只有日线，混入首发前走势·相位不对齐(open!=target_unknown) — 该行涨幅别用来定止盈止损
相似度依据:同为韩美药品肥胖/糖尿病管线授权给跨国药企，但规模低于当前且紧随Sanofi事件后。
经验:连续license-out会强化平台重估，但第二单涨幅受前序涨停和拥挤度影响。 - 相似度 6/10 128940 2019-07-04 Janssen退回Hanmi肥胖药权利后，韩美药品股价从414500韩元跌至301500韩元。 原文 ↗
测韩美药品（128940.KS）权利退回后的反应。
相似度依据:同一主体、同一肥胖管线方向，但为授权退回的反向事件，用于衡量早期管线里程碑不确定性。
经验:早期肥胖代谢授权的远期里程碑不能完全资本化，权利退回会造成剧烈反向重估。
原文全文
展开原文 · 2,062 字
Hanmi Pharmaceutical has secured the largest drug licensing deal in its history since the death of founder Lim Sung-ki, drawing fresh attention to the R&D leadership of his eldest daughter, Lim Ju-hyun, vice chairman of Hanmi Group. Industry observers say the deal, a jackpot worth more than 3 trillion won, is the result of sustained investment in drug development even amid turmoil inside and outside the group, including a dispute over management control.
Hanmi Pharmaceutical signed an exclusive license agreement on the 24th with Genentech, a subsidiary of Roche, for HM17321, a candidate treatment for obesity and metabolic disease. The deal has focused attention on the management strategy of Lim, who led the drug development project. The result stands out because it surpasses the drug development achievements of Lim Sung-ki, who died in August 2020, as the company's largest technology export to date. The agreement is worth up to about $2.3 billion (roughly 3.19 trillion won), with an upfront payment alone of $190 million (about 262.9 billion won).
HM17321 is the core pipeline of "H.O.P," an obesity and metabolic disease project designed and driven by the vice chairman. "H.O.P" aims to build a full-cycle treatment solution for obesity, and Hanmi Pharmaceutical is running a total of six pipelines, including efpeglenatide, HM15275, HM17321 and HM500197.
The industry views the achievement as the fruit of Lim Ju-hyun carrying on the founder's R&D-centered management philosophy. Even as Hanmi Group endured severe turmoil from a management control dispute and other issues following the founder's death, it continued to invest in and support drug development.
A Hanmi Pharmaceutical official said the ability to focus on drug development amid the turmoil following the founder's death was underpinned by the vice chairman's full backing. "Without the role of supporting our members so they could concentrate on research and shielding them from various external pressures, it would have been difficult to achieve this result," the official said.
Hanmi Pharmaceutical signed an exclusive license agreement on the 24th with Genentech, a subsidiary of Roche, for HM17321, a candidate treatment for obesity and metabolic disease. The deal has focused attention on the management strategy of Lim, who led the drug development project. The result stands out because it surpasses the drug development achievements of Lim Sung-ki, who died in August 2020, as the company's largest technology export to date. The agreement is worth up to about $2.3 billion (roughly 3.19 trillion won), with an upfront payment alone of $190 million (about 262.9 billion won).
HM17321 is the core pipeline of "H.O.P," an obesity and metabolic disease project designed and driven by the vice chairman. "H.O.P" aims to build a full-cycle treatment solution for obesity, and Hanmi Pharmaceutical is running a total of six pipelines, including efpeglenatide, HM15275, HM17321 and HM500197.
The industry views the achievement as the fruit of Lim Ju-hyun carrying on the founder's R&D-centered management philosophy. Even as Hanmi Group endured severe turmoil from a management control dispute and other issues following the founder's death, it continued to invest in and support drug development.
A Hanmi Pharmaceutical official said the ability to focus on drug development amid the turmoil following the founder's death was underpinned by the vice chairman's full backing. "Without the role of supporting our members so they could concentrate on research and shielding them from various external pressures, it would have been difficult to achieve this result," the official said.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。